Group 1 - The core viewpoint is that major companies are accelerating their computing power layout, and there is a sustained optimism for the Hong Kong stock technology sector's leading role, particularly in the allocation value of internet heavyweight assets [1] - The Q3 earnings season for the internet sector has concluded without significant narrative changes, with expectations for individual stock EPS recovery, especially for those previously impacted by competition, and a long-term valuation uplift driven by AI options for next year [1] - The recommendation is to strategically invest in fundamentally sound Hong Kong technology assets that benefit from AI catalysts during market dips [1] Group 2 - The Hong Kong Technology ETF (513020) tracks the Hong Kong Stock Connect Technology Index (931573), covering core assets in sectors such as internet, innovative pharmaceuticals, and new energy vehicles, reflecting the diversified characteristics of the technology industry and overall performance of core technology companies in the Hong Kong market [1] - The Hong Kong Stock Connect Technology Index has a higher allocation in new energy vehicles and innovative pharmaceuticals compared to the Hang Seng Technology Index, with a cumulative return of 256.46% from the base date at the end of 2014 to October 2025, outperforming the Hang Seng Technology Index (96.94%) by nearly 160% [1]

Group 1 - The Hong Kong Innovative Drug ETF (513120) experienced a decline of 0.44% on December 1, with a trading volume of 3.824 billion yuan [1] - The fund's shares increased by 4 million, bringing the total shares to 18.690 billion, with a notable increase of 1.290 billion shares over the last 20 trading days [1] - The latest net asset value of the fund is calculated at 25.209 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Innovative Drug ETF is the return rate of the China Securities Hong Kong Innovative Drug Index (denominated in RMB) [1] - The fund is managed by Guangfa Fund Management Co., Ltd., with Liu Jie as the fund manager [1] - Since its inception on July 1, 2022, the fund has achieved a return of 34.87%, while the return over the past month is -0.55% [1]

Core Insights - The article discusses the performance of public funds in a structurally rising market, highlighting the contrast between successful funds and those struggling, referred to as "five-dime funds" [1] - It emphasizes the importance of fundamental analysis, diversification, and effective risk management for fund managers to navigate market cycles successfully [1] Fund Performance Overview - Active equity funds have shown strong performance this year, with the mixed equity fund index rising over 28%. However, many funds have missed opportunities, with 84 active equity funds having a net value below 0.6 yuan as of November 28, and 20 of those below 0.5 yuan [2] - A specific example is the Dongfang Alpha Zhaoyang Mixed Fund, which has a net value of 0.4193 yuan and has lost over 17% this year, primarily due to a concentrated bet on the military industry sector [2] Notable Fund Management Issues - The Huiquan Zhenxin Zhiyuan Mixed Fund, managed by well-known investor Liang Yongqiang, has only returned 5.75% this year and has lost over 50% since inception. The fund has seen multiple changes in management, with significant losses during these transitions [3] Successful Turnarounds - Some previously underperforming funds have successfully recovered, such as Hengyue Advantage Selected Mixed Fund and Huatai Bairui Quality Selected Mixed Fund, which have seen their net values rise above 1 yuan as of November 28 [4] - The Hui Tianfu Hong Kong Advantage Selected Mixed Fund, which switched its holdings to the innovative drug sector, has seen a recovery with over 140% returns this year, reaching a net value of 1.6454 yuan [5] Strategic Adjustments - The Hengyue Advantage Selected Mixed Fund has achieved over 136% returns this year, primarily due to a strategic shift towards storage concept stocks and AI-related investments [6][7] - Fund managers are increasingly focusing on risk management and portfolio diversification to avoid heavy losses during market fluctuations [8] Investor Behavior and Market Dynamics - Despite some funds recovering, many investors have chosen to redeem their shares after net value increases, indicating a lack of confidence in long-term holding [8] - High volatility in fund net values can lead to frequent trading by investors, which diminishes overall returns and creates a cycle of higher risk with lower rewards [9]

第二大致损原因是硬件龙头公司。"最近两个月，第一重仓硬件龙头公司，持续下跌，跌幅超过37%，在这两个月回撤里面-9%以上的净值负贡献。"梁宏介 绍，该股最初建仓于30多元/股，后期在高位加仓，平均成本约为40多元/股。尽管公司在人工智能硬件入口逻辑上具备生态卡位优势，且一度预计2024年净 利润可达700亿元，但受存储芯片价格上涨影响，消费电子终端销售承压，叠加负面舆情发酵，尤其是成都事故引发舆论关注，汽车业务前景被重新评估。 第三大致损原因是美股稳定币股。"几个月前公司重仓介入了美股稳定币股。该股上市后一度股价冲到300美元/股，随后该标的股价调整50%-60%以后希瓦 买入。但该股票属于新股上市，后续出现了巨量低成本股份解禁，而且我忽略了加密货币行业反转带来的巨大负面影响。近四周该标的的调整对组合造成了 4%-5%的净值下跌。"梁宏直言。 这三次失误加起来造成了18%的净值回撤，再加上一些跟随指数的正常下跌，最终酿成了希瓦私募20%的累计回撤。 希瓦私募最新周报显示，该私募旗下多数基金周度预估净值下跌7%左右，从最高点累计回撤幅度约为20%，本次回撤大幅度跑输主要指数，主因还是个股 问题，其次是科技互联网 ...

Core Insights - The report indicates that the market is expected to experience an early "spring rally" due to easing external pressures and improving internal conditions [2][3] - The focus for December should be on growth sectors, particularly those aligned with the "14th Five-Year Plan" and new productive forces [3] Group 1: Market Environment - In November, market momentum was limited due to seasonal effects and external pressures, including tightening global liquidity and concerns over AI industry bubbles [1] - As of December, the pressure on the A-share market is gradually easing, with an 80% probability of a short-term interest rate cut by the Federal Reserve, creating a warmer overall atmosphere [2] - The sentiment around AI stocks has stabilized, reducing the emotional pressure on related A-share sectors [2] Group 2: Investment Recommendations - The report suggests focusing on two main directions for investment in December: the AI industry chain and sectors related to the "14th Five-Year Plan" [3] - Specific sectors to watch include chip design, semiconductor equipment, and platform companies with full-stack technical capabilities [4] - High-growth areas such as energy storage and innovative pharmaceuticals are highlighted as potential investment opportunities [4] Group 3: Top Stock Picks - The report lists ten recommended stocks, including: - BeiGene (688235.SH) in the pharmaceutical sector, with a projected EPS growth from 3.66 in 2026 to 6.73 in 2027 [5] - Haisco (002653.SZ), also in pharmaceuticals, with a projected EPS of 0.70 in 2026 and 0.81 in 2027 [5] - Longking (600388.SH) in environmental services, with a projected EPS of 1.20 in 2026 and 1.37 in 2027 [5] - Maiwei (300751.SZ) in machinery, with a projected EPS of 3.14 in 2026 and 3.93 in 2027 [5] - Yutong Bus (600066.SH) in the automotive sector, with a projected EPS of 2.67 in 2026 and 3.18 in 2027 [5] - Cambricon (688256.SH) in electronics, with a projected EPS of 11.64 in 2026 and 20.88 in 2027 [5] - CATL (300750.SZ) in new energy, with a projected EPS of 18.90 in 2026 and 23.35 in 2027 [5] - Alibaba (9988.HK) in media and internet, with a projected EPS of 4.33 in 2026 and 6.44 in 2027 [5] - Xianle Health (300791.SZ) in food and beverage, with a projected EPS of 1.37 in 2026 and 1.64 in 2027 [5] - Wanhua Chemical (600309.SH) in energy and chemicals, with a projected EPS of 5.13 in 2026 and 5.79 in 2027 [5] Group 4: Financial Data - The report provides financial forecasts for the top stock picks, indicating expected revenue and net profit growth across various sectors [62][63] - For example, BeiGene is projected to achieve a revenue of 370.27 billion in 2025, increasing to 462.80 billion in 2026 [63] - CATL is expected to see significant growth, with projected revenues of 4226.04 billion in 2025 and 5349.47 billion in 2026 [63]

Report Industry Investment Rating No information provided. Core Viewpoints of the Report - In 2026, the uncertainty in the macro - environment is expected to decline. China's economic growth may be driven by rebalancing, with a slight slowdown to 4.7%. The US economy may be driven by fiscal - stimulated consumption and AI investment, and there may be three 25 - basis - point interest rate cuts by the end of next year [3][10]. - In the Chinese market, valuation growth will shift from being liquidity - driven to profit - driven. Hong Kong stocks are cost - effective. Investment should focus on high - growth stocks and core asset themes such as overseas expansion, AI, and new consumption [3][10]. - In the consumer industry, the competitive environment is expected to improve. The investment strategy is to embrace new trends and new consumption. Traditional consumer industries offer opportunities in individual stock fundamental reversals, while new consumer companies focus on valuation rebounds after improved performance certainty [3][10]. - The pharmaceutical industry is optimistic. The innovative drug and CXO sectors are recommended due to factors like China's innovative drug R & D capabilities, policy support, and expected improvement in overseas biopharmaceutical investment and financing [4][10]. - The AI industry in the technology sector will continue to grow strongly, driving the growth of multiple industries and experiencing explosive demand growth in downstream applications [4][10]. Summary According to Related Catalogs 2026 China Macroeconomic Outlook: The Road to Economic Rebalancing in the First Year of the 15th Five - Year Plan - **Core Situation in 2025**: Thanks to pre - emptive policy efforts and better - than - expected external demand, the annual economic growth target of about 5% can be achieved. However, economic development still faces challenges such as imbalance between supply and demand, the unstable real estate industry, and low inflation [11][16]. - **2026 Outlook**: - **External and Internal Uncertainties**: External trade relations between China and the US may reach a new dynamic balance, and internal risks such as local government debt and real estate have decreased [17]. - **Challenges**: Economic imbalance persists, the real estate industry remains unstable, and low inflation affects investment and consumption confidence [18][19]. - **Policy**: Fiscal policy will maintain a 4.0% budget deficit rate, issue 1.6 trillion yuan in ultra - long - term special treasury bonds, and may increase local government special bonds. It focuses on promoting consumption and stabilizing investment. Monetary policy will remain loose, with possible interest rate cuts of 10 - 20 basis points and reserve requirement ratio cuts of 50 - 100 basis points. Real estate policies will be moderately advanced [21][22]. - **Economic Growth**: Real economic growth is expected to slow to 4.7%. Consumption and investment will contribute 4.3 percentage points, higher than in 2025. The economic growth rate may be low in the first half and high in the second half. Inflation is expected to improve, with the CPI rising to 0.6% and the nominal GDP growth rate rising to 4.5%. The US dollar - RMB exchange rate will remain stable [23][24]. 2026 US Macroeconomic Outlook: The Road to Economic Recovery Led by Policy Stimulus No information provided. 2026 China Market Strategy Outlook: Demand - Driven Growth, Embracing New Core Assets - **Investment Strategy**: China's market liquidity will remain abundant, but valuation growth will be profit - driven. Hong Kong stocks are cost - effective. Investment should focus on high - growth stocks and core asset themes like overseas expansion, AI, and new consumption [10]. Consumer Industry 2026 Outlook: Find Opportunities in the Quiet and the Ordinary - **Industry Environment**: In a weak demand recovery environment, the competitive environment is expected to improve through upstream capacity reduction, downstream inventory clearance, and anti - involution [10]. - **Investment Strategy**: The key is to embrace new trends and new consumption. High - cost - performance domestic substitution, emotional consumption, health - related consumption, new retail formats, and domestic brands going overseas are important investment directions. Traditional consumer industries focus on individual stock fundamental reversals, and new consumer companies focus on valuation rebounds [10]. - **Preferred Stocks**: Pop Mart (9992.HK), Luckin Coffee (LKNCY.US), and Topsports (6110.HK) are preferred in 2026 [10]. Pharmaceutical Industry 2026 Outlook: Reach New Heights - **Optimistic Outlook**: The pharmaceutical sector is optimistic. The innovative drug sector is recommended due to China's leading R & D capabilities, policy support, and more biotech companies entering the profit stage. The CXO sector is also promising as overseas biopharmaceutical investment and financing is expected to improve [4][10]. Technology Industry 2026 Outlook: AI Algorithm Iteration Expands the Computing Power Base, and the Prosperous Ecosystem Reshapes the Growth Boundary - **AI Growth**: The AI industry will continue to grow strongly. Its underlying technology is in a flywheel - iteration stage, driving the growth of multiple industries and experiencing explosive demand growth in downstream applications such as C - end, B - end, and G - end. In the long run, it may bring growth to emerging industries like embodied intelligence [4][10].

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Views - The retail pharmacy sector is expected to benefit from the recent surge in flu cases, with a significant increase in demand for antiviral medications and symptomatic treatments [5][15] - The retail pharmacy industry is anticipated to undergo accelerated consolidation, with smaller pharmacies exiting the market, leading to increased customer traffic for leading players [6][34] - The implementation of drug traceability codes is expected to enhance industry compliance and further increase market concentration [6][18] Summary by Sections Industry Overview - The closing index for the industry is 8430.03, with a 52-week high of 9323.49 and a low of 6764.34 [2] Recent Market Performance - The A-share pharmaceutical sector rose by 2.67% from November 24 to November 28, 2025, outperforming the CSI 300 index by 1.03 percentage points [19][35] - The Hang Seng Healthcare Index increased by 3.64%, outperforming the Hang Seng Index by 1.1 percentage points [35][36] Industry Insights and Investment Recommendations 1. **Innovative Drugs**: The long-term trend for innovative drugs is positive, with China's capabilities in global competition strengthening [9][21] - Recommended stocks include Innovent Biologics, Kintor Pharmaceutical, and others [10][22] 2. **Medical Devices**: The medical device sector is showing signs of recovery, with leading companies reporting improved performance in Q3 [10][26] - Recommended stocks include Mindray, Aohua Endoscopy, and others [27][28] 3. **Traditional Chinese Medicine**: The sector is under pressure but is expected to benefit from basic drug policies and innovation [31][32] - Recommended stocks include Zhaoke Ophthalmology, Fangsheng Pharmaceutical, and others [31][32] 4. **Retail Pharmacy**: The retail pharmacy sector is expected to see increased concentration, with leading pharmacies benefiting from enhanced service capabilities and supply chain management [6][34] - Recommended stocks include Yifeng Pharmacy and Dazhong Pharmacy [7][34]

Group 1: Non-ferrous Metals - The non-ferrous metal sector has shown a steady recovery in revenue and profit growth, with midstream smelting and processing profits rebounding [2] - The sector's profitability continues to improve, with a decrease in leverage ratios and cash flow growth maintaining an upward trend [2] - Positive factors for metals such as silver, copper, tin, and rare earths are driving price increases, with continued optimism for metals like gold, silver, copper, aluminum, and lithium [2] Group 2: Communication - The global quantum technology industry is expected to grow at a CAGR of 76.27% from 2024 to 2030, with a projected market size of $908.91 billion by 2035 [3] - The demand for isolators is expected to grow alongside the surge in optical module demand, becoming a significant upstream component [3] - The communication ETF has seen a 3.01% increase, with over 60% growth year-to-date [3] Group 3: Chip Industry - ByteDance's Doubao team has launched a technical preview of the Doubao mobile assistant, which integrates AI capabilities for enhanced user interaction [4] - The semiconductor industry is anticipated to benefit from AI-driven hardware opportunities and domestic substitution processes amid external restrictions [4] - The chip ETF has increased by 1.82%, being the only product in its category to show positive growth year-to-date [4] Group 4: Agriculture, Forestry, Animal Husbandry, and Fishery - The agricultural sector is stabilizing as China continues to promote seed industry revitalization and improve grain yields [6] - Global weather disruptions may lead to a decrease in overall crop yields, potentially improving the agricultural industry's outlook [6] - The grain ETF is gaining attention as it covers the entire grain industry chain [6] Group 5: Hong Kong Innovative Drugs - The innovative drug sector is experiencing a temporary sentiment decline, but the overall trend remains positive with ongoing internationalization [7] - The largest Hong Kong innovative drug ETF has reached a scale of 25.276 billion yuan, indicating significant market interest [7] Group 6: Manufacturing PMI - China's manufacturing PMI for November was reported at 49.2%, showing a slight improvement from October [9] - The production index and new orders index have increased, indicating a recovery in manufacturing activity [9] Group 7: Engineering Machinery - The engineering machinery sector is witnessing a recovery in demand, with sales of excavators and loaders continuing to grow [10] - The industry is expected to benefit from ongoing domestic investment strategies and major project implementations [10] - The largest engineering machinery ETF has seen continuous net inflows over the past three days [10]

Group 1 - The core viewpoint is that global giants are significantly increasing capital expenditure, shifting the market focus towards the commercialization of AI applications in the coming year [1] - AI is expected to continue its rapid penetration, with mature terminal hardware technology, clear implementation paths, and quick value realization [1] - Domestic manufacturing leaders are deeply integrated into the supply chains of top terminal brands, creating competitive barriers in core components and assembly processes due to their vertical integration capabilities and global supply chain layout [1] Group 2 - The Hong Kong Technology ETF (513020) tracks the Hong Kong Stock Connect Technology Index (931573), covering core assets in Hong Kong such as Internet, semiconductors, innovative pharmaceuticals, and new energy vehicles [1] - The Hong Kong Stock Connect Technology Index has a higher allocation in new energy vehicles, innovative pharmaceuticals, and semiconductors compared to the Hang Seng Technology Index [1] - From the base date at the end of 2014 to the end of October 2025, the cumulative return of the Hong Kong Stock Connect Technology Index is 256.46%, outperforming the Hang Seng Technology Index by nearly 160% [1]

Group 1: Federal Reserve and Market Expectations - Goldman Sachs indicates that the Federal Reserve is expected to lower interest rates during the December 9-10 meeting, with a nearly certain probability of a 25 basis point cut at around 85%-86% [1] Group 2: Company Developments - Baillie Gifford's subsidiary SystImmune received a $250 million milestone payment from Bristol-Myers Squibb related to the global strategic collaboration agreement, with potential for up to $2.5 billion in near-term or contingent payments and an additional $7.1 billion upon achieving specific development, registration, and sales milestones [1] - Innovent Biologics announced that its self-developed drug, Xinmeiyue® (Pikankizumab injection), has been approved by the National Medical Products Administration (NMPA) for the treatment of moderate to severe plaque psoriasis in adult patients, marking a significant advancement in domestic precision treatment for psoriasis [1] Group 3: Market Performance and Trends - The Hong Kong Stock Connect Innovation Drug ETF (159570) experienced a decline of over 1% for two consecutive days, with a trading volume exceeding 1 billion yuan, and a net inflow of 80 million yuan during the day [3] - As of November 29, the latest scale of the Hong Kong Stock Connect Innovation Drug ETF (159570) exceeded 24 billion yuan, leading its peers in the same category [3] Group 4: Upcoming Events and Industry Catalysts - The results of the drug catalog negotiation conducted by the Medical Insurance Bureau are expected to be released in the first weekend of December, with a focus on the inclusion of domestic biological innovative drugs for skin diseases in the medical insurance [4] - The American Society of Hematology (ASH) conference is set to take place from December 6-9, where multiple differentiated hematology products will have data disclosed, with a focus on companies like BeiGene, Innovent Biologics, and others [4] Group 5: Company Stock Performance - The weighted stocks of the Hong Kong Stock Connect Innovation Drug ETF (159570) showed mixed performance, with major stocks like Rongchang Bio down over 5%, while Innovent Biologics and Hansoh Pharmaceutical saw slight increases [1][2]